PURPOSE: The incidence of @entity5 is approximately 2% among all head and @entity135 , of which malignant cases account for only about 5%. Much research has been performed in order to clarify the mechanism of oncogene activation, however @entity5 remain understudied. We performed this study in order to characterize the ras gene in these @entity5 . MATERIALS AND METHODS: We treated white @entity35 with @entity3653 (DMBA) and confirmed the occurrence of @entity5 after ten to thirty weeks. Isolated genomic DNAs from @entity5 tissues were added to NIH 3T3 cells. In order to detect Ha-ras mutations, we performed a two-step PCR-RFLP and 7analyzed the mutated sequences. RESULTS: We induced @entity5 by DMBA treatment in white @entity35 . Isolated DNAs from the @entity5 tissues transformed the NIH 3T3 cells. Point mutations were observed in codons 12 and 61 of the Ha-ras oncogene. The total frequency of point mutations was 13.9% in DMBA-induced @entity5 in @entity35 . CONCLUSION: Our results demonstrate that a variety of @entity5 ras oncogene mutations were also found in @entity5 . We confirmed that a point mutation of the Ha-ras oncogene in a DMBA-induced @entity5 occurs at a frequency of 13.9%.

Mutation of Ha-ras Oncogene in XXXX Salivary Gland Tumors Induced by DMBA.

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'salivary gland tumor', 'cancers', 'salivary gland tumors', 'tumors'] @entity135 :: ('MESH:D006258', 'Disease') :: ['neck tumors'] @entity3653 :: ('CHEBI:254496', 'Chemical') :: ['7, 12-dimethylbenz[a]anthracene'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity35 :: (10116,Species) :: ['Rat']
